Xellar Biosystems
Overview
Xellar Biosystems is an innovative biotechnology company that specializes in advanced drug discovery using AI-driven Organ-on-a-Chip technology. Founded in 2021 by Xin Xie, a former engineer at TransMedics, Xellar aims to address the complexities of human biology to expedite drug development. The company is headquartered in Cambridge, Massachusetts and has raised a total of $23.8 million to date, with a recent funding of $14 million in 2024 from investors like TriApex Laboratories, Zhengxuan Investment, and Legend Capital.
Recent Developments
- July 2024: Xellar Biosystems completed an angel funding extension round worth around 100 million yuan ($14 million) led by TriApex Laboratories, along with returning investors Yael Capital and Legend Capital. This is aimed to accelerate the development of its AI-driven organ-on-chip platform.
- June 2024: Xellar's OC-Plex8/32 organ chip device received the Q2 Product Award for excellence in biotech tools, acknowledging its innovation in drug testing and high-throughput culture systems.
- February 2024: The company joined NVIDIA Inception, a program that supports AI startups, enhancing their technical and resource capabilities through collaboration and cutting-edge research.
- December 2023: Appointment of Dr. Aiping Bai as Associate Director to bolster Xellar’s leadership in biosciences.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2021/2022 |
| Headquarters | Cambridge, Massachusetts/Beijing, China |
| Founders | Xin Xie Ph.D. |
| Revenue | Not Publicly Available |
| Profits | Not Publicly Available |
| Key Investors | TriApex Laboratories, Zhengxuan Investment, Legend Capital, Yael Capital |
| Industry | Biotechnology, AI-driven drug discovery |
| Number of Employees | 21 |
Early History
Xellar Biosystems was born from the vision of its founder Xin Xie, who embarked on this venture after acquiring invaluable experience at Harvard and TransMedics. Combining expertise in organ-on-chip technology and the burgeoning potentials of AI and machine learning, Xellar set forth to revolutionize traditional drug discovery methods. By integrating multifaceted biological models, the company spearheaded advancements through large-scale, high-content wet-lab experiments.
Company Profile and Achievements
Xellar operates on an innovative AI-driven biotechnology platform, enabling drug discovery through the implementation of its Organ-on-a-Chip models. The company's unique systems mimic human organ environments more accurately than previous simplistic models, allowing for superior evaluation of drugs concerning efficacy and toxicity.
- OC-Plex8/32: A flagship product that garnered industry accolades for its cutting-edge microfluidic design tailored for 3D cell cultures and grand-scale testing.
- Through strategic partnerships with international research stakeholders, Xellar has continuously outpaced conventional methodologies in precision and predictive capabilities in drug testing.
Current Operations and Market Position
Currently, Xellar Biosystems operates within the rapidly evolving biotechnology market, focusing on high-impact AI integration. With its headquarters in the innovation-centric locales of Cambridge and Beijing, Xellar’s market share is progressively growing. The firm prides itself on blending automation and scalable technology, positioning itself as a forerunner in transforming drug discovery landscapes. The collaborations with tech giants like NVIDIA and significant biotechnology firms further amplify its market leverage.
Xellar Biosystems Owner
Xin Xie, the company's founder and CEO, drives Xellar’s strategic vision and fosters its public and private investor engagements.
Xellar Biosystems Funding
Xellar Biosystems' funding journey has been significantly supported by ventures such as TriApex Laboratories, indicating robust faith in their groundbreaking biotechnology platforms. As of July 2024, the firm successfully completed substantial funding rounds, underscoring a resilient trajectory toward advanced organ-chip technologies.
Conclusion
Xellar Biosystems stands as a beacon of innovation in the drug discovery domain, marked by its groundbreaking organ-chip technologies and AI integration. As it moves forward, the company is poised to not only augment its current offerings but also redefine biotechnology's capability benchmark. With sustained investment, technological partnerships, and expanding market reach, Xellar is set on a transformative path that promises to reshape modern drug discovery methodologies globally.